EMA reportedly expected to approve use of Pfizer vaccine today

21/12/2020 | 07:33 GMT

NYT reports on the matter

This is very much an expected development since last week already and given the risk and dollar pullback on the day, I doubt the headline here will do much to overshadow things as we look towards the trading day ahead.

ADVERTISEMENT - CONTINUE READING BELOW

Best in 2026

Sponsored

General Risk Warning

Best Prop Firm in 2026: Detailed Comparison

Best Futures Brokers in USA for 2026: Detailed Comparison

Best Prediction Market Platforms in 2026: Detailed Comparison

Best Forex Brokers in 2026: Detailed Comparison

Best Online Brokers in 2026: Detailed Comparison

ADVERTISEMENT - CONTINUE READING BELOW

Telegram Community

Gain Access

CAVA's 172x P/E & falling EPS raise red flags. AVAV's margins shrink, EE's gross margin lags. Seek better growth.

StockStory

4m ago

XPOF faces flat sales & margin losses (9.3x P/E), while XYL & JBTM show strong growth & higher P/E ratios.

StockStory

13m ago

AMD's 75% surge is justified by 35% revenue growth targets & $20 EPS potential. Valued at 17x future earnings, it's a reasonable buy.

Motley Fool

24m ago

HDSN sales & EPS drop 7.6% & 39.1%; RMD grows 9.1% with strong FCF; TPL revenue up 26.2% with 95% gross margin.

StockStory

27m ago

NCNO, PYPL, CUBI show cash but slow growth & low margins. Avoid these, seek high revenue growth alternatives.

StockStory

37m ago

ROST, FSLR, WHD show strong returns & growth. ROST at 30.6x P/E, FSLR at 9.7x, WHD at 19.2x. Buy signals?

StockStory

49m ago

VTS boasts 10.3% revenue growth & 79.8% gross margin, but trades at 67.5x P/E.

StockStory

52m ago

Telegram Community

Gain Access

Must Read

!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}